Eisai is expanding the scope of its cancer drug pipeline through a partnership with Bliss Biopharmaceutical, whose lead program addresses a hot oncology target that makes it a potential competitor to a blockbuster AstraZeneca product.
Under the collaboration agreement announced Monday,…
Source: medcitynews.com – Read more
Eisai Strikes Cancer Alliance to Line Up Potential Challenger to AstraZeneca Drug
Must Read
The Top 10 endpoint security challenges and how to overcome them
Join top executives in San Francisco on July 11-12, to hear how leaders are integrating and optimizing AI investments for success. Learn More
One of...
